GORE Septal Occluder receives FDA approval for use in REDUCE clinical study

Published on October 22, 2012 at 10:38 AM · No Comments

W. L. Gore & Associates (Gore) today announced that the FDA has approved the use of the new GORE® Septal Occluder for inclusion in the Gore REDUCE Clinical Study. Gore is introducing this latest technology in its Gore REDUCE Clinical Study for prevention of recurrent stroke in patent foramen ovale (PFO) patients. The study is designed to demonstrate that PFO closure with the Gore device plus antiplatelet medical management reduces the risk of recurrent stroke or imaging-confirmed Transient Ischemic Attack (TIA) when compared to antiplatelet medical management alone. The prospective, randomized, multi-center, multi-national trial includes up to eighty investigational sites in the US, Europe and Canada.

“We have seen great success with the GORE Septal Occluder since we completed the first implant. The device provides ease of deployment and confidence through design for the patient's well being”

The new Gore device received CE Mark in June of 2011 for the indication of PFO and atrial septal defect (ASD) closure. Dr. Lars Sondergaard, Nordic Region Cardiology Principal Investigator for the Gore REDUCE Clinical Study, performed the first European procedures using the Gore device. "We have seen great success with the GORE Septal Occluder since we completed the first implant. The device provides ease of deployment and confidence through design for the patient's well being," said Sondergaard.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post